TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Prelude Therapeutics
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Prelude Therapeutics presented preclinical data on two promising therapeutic approaches for myeloproliferative neoplasms (MPNs): a JAK2V617F-selective JH2 inhibitor (PRT12396) and a mutant calreticulin targeted degrader antibody conjugate, demonstrating potential disease-modifying capabilities.

Insights
AMZN   neutral

Dropped as a major customer, perceived as focusing on cost-cutting rather than comprehensive employee benefits


PRLD   positive

Company presented promising preclinical data for two novel therapeutic approaches, completed toxicology studies, and is on track to file an IND in Q1 2026, indicating strong scientific progress and potential for innovative treatments